speb/financial-data huggingface dataset:
AJA.V balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 211421.00
AJA.V balance_sheet (annual, 2023-12-31) — Total Tax Payable: 38510.00
AJA.V balance_sheet (annual, 2023-12-31) — Working Capital: -2458211.00
AJA.V income_statement (quarterly, 2024-09-30) — +Operating Expense: 2581834.00
AJA.V income_statement (quarterly, 2024-09-30) — +Total Revenue: 131101.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 494315.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 43782.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Accumulated Depreciation: -226597.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Additional Paid In Capital: 1862463.00
AJA.V income_statement (quarterly, 2024-09-30) — Basic Average Shares: 86003979.00
AJA.V income_statement (quarterly, 2024-09-30) — Basic EPS: -0.03
AJA.V cash_flow (quarterly, 2024-09-30) — Beginning Cash Position: 239836.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Buildings And Improvements: 360403.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 147152.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Capital Stock: 13158904.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 2192849.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 2192849.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Cash Financial: 2192849.00
AJA.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Financing Activities: 2327815.00
AJA.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Operating Activities: -48347.00
AJA.V cash_flow (quarterly, 2024-09-30) — Change In Payable: 358138.00
AJA.V cash_flow (quarterly, 2024-09-30) — Change In Payables And Accrued Expense: 358138.00
AJA.V cash_flow (quarterly, 2024-09-30) — Change In Prepaid Assets: -106250.00
AJA.V cash_flow (quarterly, 2024-09-30) — Change In Receivables: 22141.00
AJA.V cash_flow (quarterly, 2024-09-30) — Change In Working Capital: 274029.00
AJA.V cash_flow (quarterly, 2024-09-30) — Changes In Cash: 1953013.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Common Stock: 13158904.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 2472132.00
AJA.V cash_flow (quarterly, 2024-09-30) — Common Stock Issuance: 2481397.00
AJA.V income_statement (quarterly, 2024-09-30) — Cost Of Revenue: 49904.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Current Assets: 2370474.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 585027.00
AJA.V cash_flow (quarterly, 2024-09-30) — Depreciation: 17385.00
AJA.V cash_flow (quarterly, 2024-09-30) — Depreciation Amortization Depletion: 17385.00
AJA.V income_statement (quarterly, 2024-09-30) — Depreciation Amortization Depletion Income Statement: 17385.00
AJA.V cash_flow (quarterly, 2024-09-30) — Depreciation And Amortization: 17385.00
AJA.V income_statement (quarterly, 2024-09-30) — Depreciation And Amortization In Income Statement: 17385.00
AJA.V income_statement (quarterly, 2024-09-30) — Depreciation Income Statement: 17385.00
AJA.V income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 86003979.00
AJA.V income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.03
AJA.V income_statement (quarterly, 2024-09-30) — Diluted NI Availto Com Stockholders: -2572014.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Dueto Related Parties Current: 0.00
AJA.V income_statement (quarterly, 2024-09-30) — EBIT: -2550637.00
AJA.V income_statement (quarterly, 2024-09-30) — EBITDA: -2533252.00
AJA.V cash_flow (quarterly, 2024-09-30) — End Cash Position: 2192849.00
AJA.V cash_flow (quarterly, 2024-09-30) — Financing Cash Flow: 2327815.00
AJA.V cash_flow (quarterly, 2024-09-30) — Free Cash Flow: -48347.00
AJA.V income_statement (quarterly, 2024-09-30) — General And Administrative Expense: 340641.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 652065.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Gross PPE: 408369.00
AJA.V income_statement (quarterly, 2024-09-30) — Gross Profit: 81197.00
AJA.V income_statement (quarterly, 2024-09-30) — Interest Expense: 21377.00
AJA.V income_statement (quarterly, 2024-09-30) — Interest Expense Non Operating: 21377.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Invested Capital: 2472132.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Investments And Advances: 0.00
AJA.V cash_flow (quarterly, 2024-09-30) — Issuance Of Capital Stock: 2481397.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 147152.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 147152.00
AJA.V cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: -8455.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Machinery Furniture Equipment: 47966.00
AJA.V cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: 2481397.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income: -2572014.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income Common Stockholders: -2572014.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income Continuous Operations: -2572014.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income From Continuing And Discontinued Operation: -2572014.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: -2572014.00
AJA.V cash_flow (quarterly, 2024-09-30) — Net Income From Continuing Operations: -2572013.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Income Including Noncontrolling Interests: -2572014.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Interest Income: -21377.00
AJA.V cash_flow (quarterly, 2024-09-30) — Net Issuance Payments Of Debt: -160526.00
AJA.V cash_flow (quarterly, 2024-09-30) — Net Long Term Debt Issuance: -8455.00
AJA.V income_statement (quarterly, 2024-09-30) — Net Non Operating Interest Income Expense: -21377.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Net PPE: 181772.00
AJA.V cash_flow (quarterly, 2024-09-30) — Net Short Term Debt Issuance: -152071.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 1820067.00
AJA.V income_statement (quarterly, 2024-09-30) — Normalized EBITDA: -2483252.00
AJA.V income_statement (quarterly, 2024-09-30) — Normalized Income: -2522014.00
AJA.V cash_flow (quarterly, 2024-09-30) — Operating Cash Flow: -48347.00
AJA.V income_statement (quarterly, 2024-09-30) — Operating Income: -2500637.00
AJA.V income_statement (quarterly, 2024-09-30) — Operating Revenue: 131101.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 86687740.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 90712.00
AJA.V income_statement (quarterly, 2024-09-30) — Other Gand A: 247501.00
AJA.V income_statement (quarterly, 2024-09-30) — Other Income Expense: -50000.00
AJA.V cash_flow (quarterly, 2024-09-30) — Other Non Cash Items: 2167252.00
AJA.V income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 2142920.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Payables: 494315.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Payables And Accrued Expenses: 494315.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Prepaid Assets: 133843.00
AJA.V income_statement (quarterly, 2024-09-30) — Pretax Income: -2572014.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Properties: 0.00
AJA.V income_statement (quarterly, 2024-09-30) — Provision For Doubtful Accounts: 15000.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Receivables: 43782.00
AJA.V income_statement (quarterly, 2024-09-30) — Reconciled Cost Of Revenue: 49904.00
AJA.V income_statement (quarterly, 2024-09-30) — Reconciled Depreciation: 17385.00
AJA.V cash_flow (quarterly, 2024-09-30) — Repayment Of Debt: -8455.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Retained Earnings: -12549235.00
AJA.V income_statement (quarterly, 2024-09-30) — Salaries And Wages: 93140.00
AJA.V income_statement (quarterly, 2024-09-30) — Selling And Marketing Expense: 65888.00
AJA.V income_statement (quarterly, 2024-09-30) — Selling General And Administration: 406529.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Share Issued: 86687740.00
AJA.V income_statement (quarterly, 2024-09-30) — Special Income Charges: -50000.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 2472132.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 1820067.00
AJA.V income_statement (quarterly, 2024-09-30) — Tax Effect Of Unusual Items: 0.00
AJA.V income_statement (quarterly, 2024-09-30) — Tax Rate For Calcs: 0.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Assets: 3204311.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 2472132.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Debt: 147152.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 2472132.00
AJA.V income_statement (quarterly, 2024-09-30) — Total Expenses: 2631738.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 732179.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 833837.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 147152.00
AJA.V income_statement (quarterly, 2024-09-30) — Total Unusual Items: -50000.00
AJA.V income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: -50000.00
AJA.V balance_sheet (quarterly, 2024-09-30) — Working Capital: 1785447.00
AJA.V income_statement (quarterly, 2024-09-30) — Write Off: 50000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -6834200000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 26300000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -147400000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Amortization: 39400000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 39400000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 6303400000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 2063600000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: 487100000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 917500000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 79400000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 9100000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 251000000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 4551100000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 951500000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 10345500000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 171000000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Impairment Of Capital Assets: 39800000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Interest Income: 146500000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 146500000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Investment Properties: 84100000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Investmentsin Joint Venturesat Cost: 0.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 2300000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 2200900000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 16400000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 2300000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 0.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 13275500000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: -681900000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 30000000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 193200000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 118800000.00
AJANTPHARM.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: -2391300000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 494100000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 5401800000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Other Payable: 783300000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Other Special Charges: 38700000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 108100000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 437900000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 2400500000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 65400000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 65400000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 54200000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 27177000000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 2185700000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 3137200000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Special Income Charges: -78500000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 439400000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 215200000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 215200000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 10900000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Treasury Shares Number: 4200000.00
AJANTPHARM.NS balance_sheet (annual, 2022-03-31) — Work In Process: 465000000.00
AJANTPHARM.NS income_statement (annual, 2022-03-31) — Write Off: 0.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — +Operating Expense: 19110300000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — +Total Revenue: 37075200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 4227700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 10569000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -7622500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 4400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -110400000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Amortization: 41000000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 41000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 88200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 39000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Average Dilution Earnings: 0.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 128118877.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Basic EPS: 45.89
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 2063600000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 6427700000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -1744900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure Reported: -1744900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 342000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 252700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 3298300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 8401000000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -896900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 465000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 2833300000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -223700000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 404900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -323800000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Payable: 969100000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -215700000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 668500000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 1243100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock: 252700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 33879900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -14400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 2094700000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 11167300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Assets: 28340000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 92500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1800000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 94300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Deferred Taxes Liabilities: 330700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 11392800000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 1864300000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation: 1267000000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 1308000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 1308000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 1267000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 128122871.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Diluted EPS: 45.89
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 5879800000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 8200000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — EBIT: 7510900000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — EBITDA: 8818900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — End Cash Position: 3306700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 251000000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -1082000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 4470600000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 6176200000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: 34800000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 61900000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1159700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 77500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 10679400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 24604100000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Gross Profit: 25907900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 0.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Impairment Of Capital Assets: 200000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense: 58400000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 58400000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Interest Income: 84600000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 84600000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -23300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Inventory: 8156300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 33894200000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -5596000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Investment Properties: 0.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 290000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Investmentsin Joint Venturesat Cost: 0.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 2202500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 249500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 12500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 262000000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -4900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 0.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 241500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 13879200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 0.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -14400000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -140800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income: 5879800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 5879800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 5879800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 5879800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 5879800000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 7452500000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 5879800000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Interest Income: 26200000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -3863600000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -4900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -4900000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 26200000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -11100000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 5200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Net PPE: 16981600000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: 7300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 33802400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 26700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 967700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 977200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 241500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 110100000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 8912400000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Normalized Income: 5953571500.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 7921100000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Operating Income: 6797600000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Operating Revenue: 37075200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 126681155.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 916100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 231500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 3400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 77500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 517100000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 55100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 53200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 26700000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 61500000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 6729000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Payable: 553100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Properties: 14886900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 125800000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 5102700000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Other Special Charges: 53500000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Payables: 4789000000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 140200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 586300000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Pretax Income: 7452500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -16625100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 2644000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 11167300000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 1308000000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 75900000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 75900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -4900000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -14400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 10700000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 31412700000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 12761500000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 7300000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 2267100000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 3426800000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 126681155.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: -53500000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 2200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 33879900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 33802400000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -19728500.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 1572700000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.21
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 402700000.00
AJANTPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -1512900000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 46790200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 33892400000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 356300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 33879900000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 30277600000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 12910300000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 18450200000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1517500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 330700000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -93500000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -93500000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 10100000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 524600000.00
AJANTPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 16947200000.00
AJANTPHARM.NS income_statement (annual, 2023-03-31) — Write Off: -8400000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 20006300000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 41615900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 4632000000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 12468400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -8810400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 6200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -88300000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Amortization: 50100000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 50100000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 88500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 41600000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Average Dilution Earnings: 0.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 125915562.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 64.82
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 3298300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 6649300000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -1524100000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure Reported: -1524100000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 337900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 252700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 1294900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 4595400000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -6421700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 0.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 1294900000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -123000000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -228200000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 733400000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 976100000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -2017000000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -997800000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -2006000000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 252700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 35673700000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -3882700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2643300000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 11153200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 27309200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 102700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 14900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 117600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 447700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 8952500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 2232700000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 1303900000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 1354000000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 1354000000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 1303900000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 126006041.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 64.77
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 8161700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 7200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 11211400000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 12565400000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 1292300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 185800000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -10510600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 4860500000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 6326600000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -248300000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -34900000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1295400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 146600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 12556700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 26099000000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 30462700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 124800000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 72100000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 72100000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 277100000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 277100000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -35300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 8283600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 35688600000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: 653900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 227400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 2114300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 235200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 0.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 235200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 0.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 395400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 14692100000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -3882700000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -94200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 8161700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 8161700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 8161700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 8161700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 8161700000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 11139300000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 8161700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: 205000000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 1774200000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 600000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 600000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 205000000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -9200000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 270000000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 17288600000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: 133800000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 35527100000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 23400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 1344500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 1085000000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 395400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 49900000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 12282200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 7954199360.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 7850700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 10456400000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 41615900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 125915655.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 1330700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: -5100000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 56500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 146600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 547100000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -201200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 94400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 5000000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 35900000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 6214800000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 941200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 14645300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 233400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 3300500000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Other Special Charges: -34900000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 5580400000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 177600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 959300000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 11139300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -20799700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2332500000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 11153200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 1354000000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 73800000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 73800000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -3882700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 12800000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 33143500000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 22573900000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 133800000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 2531200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 3826600000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 125915655.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 34900000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 54900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 35673700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 35527100000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 75699360.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 2977600000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.27
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 543000000.00
AJANTPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -3121300000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 46383900000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 35673700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 352800000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 35673700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 31159500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 10710200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 19074700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 1757700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 447700000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 283200000.00
AJANTPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 283200000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 13700000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 543500000.00
AJANTPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 18356700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 4208800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 10164300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 88500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 340000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 303700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 638900000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 7574800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 250700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 36769500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 3487600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 27947800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 88300000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 24200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 112500000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 9090100000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 211700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 133200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 17867800000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 8456600000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 36793700000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 340000000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 215400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 215400000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 672200000.00
AJANTPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 17867800000.00